Takeda presents positive results from trial of chronic kidney disease treatment
Ella Day | June 10, 2025 | News story | Research and Development |Â Â European Renal Association, Immunology, Nephrology, Takeda, autoimmune disease, immunoglobulin A nephropathy (IgAN), kidney diseaseÂ
Takeda Pharmaceuticals has announced positive results from a proof-of-concept study of mezagitamab (TAK-079) to treat patients with primary immunoglobulin A nephropathy (IgAN), a chronic kidney disease. The Japanese biopharma is now looking ahead to a prospective phase 3 trial of mezagitamab.
The data was presented at the European Renal Association Congress on 6 June 2025 in Vienna, Austria. It indicated that at week 48, IgAN patients treated with mezagitamab experienced significant benefits compared to those who received standard-of-care therapy alone. These patients achieved rapid and sustained reductions in both serum IgA and proteinuria, as well as stable renal function. Additionally, no serious adverse side effects or discontinuations were reported.
IgAN is a common autoimmune disease often diagnosed in young people (aged approximately 10 to 30 years) and is characterised by the production of abnormally formed IgA. The condition causes progressive and irreversible damage to kidney function, with around 30% of patients losing kidney function entirely, requiring a kidney transplant or life on dialysis.
Mezagitamab is a human anti-CD38 monoclonal antibody that depletes the plasma cells that produce galactose-deficient IgA1 (Gd-IgA1) and autoantibodies against GdIgA1. This intends to reduce immune complex formation, proteinuria and promote stabilisation of kidney function over time.
Ella Day
10/6/25
Related Content
A challenge we can no longer ignore: meeting the needs of people with Crohn’s Disease in the UK
By Holly Thomas, Associate Vice-President Specialty Care at Lilly UK and Ireland Immunology care in …
NICE recommends treatment for chronic kidney disease, IgA nephropathy
The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending …
EU approval granted for rare kidney disease treatment
The EU has granted marketing authorisation (MA) for Filspari – CSL Vifor and Travere Therapeutics’ …
